The 2025 guideline reclassifies 11% of older adults with stage 1 hypertension as ineligible for immediate antihypertensive therapy.
About 240,000 US adults aged 65 to 79 years may no longer qualify for drug therapy under the new individualized risk assessment.
The updated guideline shifts from age-based treatment to a focus on 10-year cardiovascular risk and high-risk comorbidities.
Among untreated patients, 89% remained eligible for pharmacotherapy, while 11% were reclassified as not needing immediate treatment.
The study highlights a trend towards personalized, risk-based care in managing hypertension among older adults.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Editor
Affiliations:
Specialties:
Areas of Expertise:
